Targets of the humoral autoimmune response in multiple sclerosis

Autoimmunity Reviews

Volumn 13, Issue 11, 2014, Pages 1126-1137

  Fraussen, Judith ^a   Claes, Nele ^a   de Bock, Laura ^a   Somers, Veerle ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

Autoantibodies; Autoantigen; Biomarker; Multiple sclerosis

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; ANGIOPOIETIN 2; AQUAPORIN 4; AUTOANTIBODY; AUTOANTIGEN; AXONIN 1; BIOLOGICAL MARKER; BULLOUS PEMPHIGOID ANTIGEN 1; CLAUDIN 11; CORONIN 1A; CRYSTALLIN; GANGLIOSIDE; GLUTAMATE DECARBOXYLASE; GLYCAN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN; MYELIN; NEUROFASCIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL KIR 4.1; PROTEIN NOGO; PROTEIN NOGO A; SWITCH ASSOCIATED PROTEIN 70; TRANSALDOLASE; TRIOSEPHOSPHATE ISOMERASE; TUBULIN; UNCLASSIFIED DRUG; ANTIGEN;

ALU SEQUENCE; ASTROCYTE; AUTOIMMUNITY; B LYMPHOCYTE; CELL TYPE; DEMYELINATION; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; MULTIPLE SCLEROSIS; NEUROFILAMENT; OLIGODENDROGLIA; PATHOGENESIS; PROGNOSIS; REVIEW; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; MYELIN SHEATH;

ANIMALS; ANTIGENS; AUTOANTIBODIES; AUTOIMMUNITY; HUMANS; IMMUNITY, INNATE; MULTIPLE SCLEROSIS; MYELIN SHEATH;

EID: 84908563903     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.07.002     Document Type: Review

References (179)

1. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
2. Lin C.H., Kadakia S., Frieri M. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmun Rev 2014, 13:114-116.
3. Antico A., Tampoia M., Tozzoli R., Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012, 12:127-136.
4. Karagkouni A., Alevizos M., Theoharides T.C. Effect of stress on brain inflammation and multiple sclerosis. Autoimmun Rev 2013, 12:947-953.
5. Ramagopalan S.V., Dobson R., Meier U.C., Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010, 9:727-739.
6. Miller D., Barkhof F., Montalban X., Thompson A., Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005, 4:281-288.
7. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
8. Milo R., Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev 2014, 13:518-524.
9. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013, 12:543-553.
10. Tullman M.J. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care 2013, 19:S21-S27.
11. Cole S.R., Beck R.W., Moke P.S., Kaufman D.I., Tourtellotte W.W. The predictive value of CSF oligoclonal banding for MS 5years after optic neuritis. Optic Neuritis Study Group. Neurology 1998, 51:885-887.
12. Kabat E.A., Glusman M., Knaub V. Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 1948, 4:653-662.
13. Fraussen J., Vrolix K., Martinez-Martinez P., Losen M., De Baets M.H., Stinissen P., et al. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun Rev 2009, 8:654-658.
14. Somers K., Govarts C., Stinissen P., Somers V. Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmun Rev 2009, 8:573-579.
15. B.D.W. Group, (2001).
16. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
17. Berger T., Reindl M. Biomarkers in multiple sclerosis: role of antibodies. Dis Markers 2006, 22:207-212.
18. Vogt M.H., Teunissen C.E., Iacobaeus E., Heijnen D.A., Breij E.C., Olsson T., et al. Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:1110-1115.
19. von Budingen H.C., Harrer M.D., Kuenzle S., Meier M., Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol 2008, 38:2014-2023.
20. 125I-labelled encephalitogenic basic protein to normal lymphocytes. Inhibition with multiple sclerosis serum. Clin Exp Immunol 1975, 19:451-458.
21. Panitch H.S., Hooper C.J., Johnson K.P. CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol 1980, 37:206-209.
22. Warren K.G., Catz I. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann Neurol 1986, 20:20-25.
23. Warren K.G., Catz I. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci 1994, 121:66-73.
24. Warren K.G., Catz I. An extensive search for autoantibodies to myelin basic protein in cerebrospinal fluid of non-multiple-sclerosis patients: implications for the pathogenesis of multiple sclerosis. Eur Neurol 1999, 42:95-104.
25. O'Connor K.C., Chitnis T., Griffin D.E., Piyasirisilp S., Bar-Or A., Khoury S., et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 2003, 136:140-148.
26. Cruz M., Olsson T., Ernerudh J., Hojeberg B., Link H. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987, 37:1515-1519.
27. Chamczuk A.J., Ursell M., O'Connor P., Jackowski G., Moscarello M.A. A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis. J Immunol Methods 2002, 262:21-27.
28. Schmidt S., Haase C.G., Bezman L., Moser H., Schmidt M., Kohler W., et al. Serum autoantibody responses to myelin oligodendrocyte glycoprotein and myelin basic protein in X-linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol 2001, 119:88-94.
29. Ponomarenko N.A., Durova O.M., Vorobiev I.I., Belogurov A.A., Telegin G.B., Suchkov S.V., et al. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett 2006, 103:45-50.
30. Belogurov A.A., Kurkova I.N., Friboulet A., Thomas D., Misikov V.K., Zakharova M.Y., et al. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 2008, 180:1258-1267.
31. Angelucci F., Mirabella M., Frisullo G., Caggiula M., Tonali P.A., Batocchi A.P. Serum levels of anti-myelin antibodies in relapsing-remitting multiple sclerosis patients during different phases of disease activity and immunomodulatory therapy. Dis Markers 2005, 21:49-55.
32. Devaux B., Enderlin F., Wallner B., Smilek D.E. Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J Neuroimmunol 1997, 75:169-173.
33. Reindl M., Di Pauli F., Rostasy K., Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013, 9:455-461.
34. Genain C.P., Cannella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999, 5:170-175.
35. Xiao B.G., Linington C., Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991, 31:91-96.
36. Reindl M., Linington C., Brehm U., Egg R., Dilitz E., Deisenhammer F., et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999, 122(Pt 11):2047-2056.
37. Gaertner S., de Graaf K.L., Greve B., Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004, 63:2381-2383.
38. Mantegazza R., Cristaldini P., Bernasconi P., Baggi F., Pedotti R., Piccini I., et al. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. Int Immunol 2004, 16:559-565.
39. O'Connor K.C., Appel H., Bregoli L., Call M.E., Catz I., Chan J.A., et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005, 175:1974-1982.
40. Wang H., Munger K.L., Reindl M., O'Reilly E.J., Levin L.I., Berger T., et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008, 71:1142-1146.
41. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139-145.
42. Kuhle J., Pohl C., Mehling M., Edan G., Freedman M.S., Hartung H.P., et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007, 356:371-378.
43. Pelayo R., Tintore M., Montalban X., Rovira A., Espejo C., Reindl M., et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med 2007, 356:426-428.
44. Chan A., Decard B.F., Franke C., Grummel V., Zhou D., Schottstedt V., et al. Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis. Mult Scler 2010, 16:1189-1192.
45. Tejada-Simon M.V., Hong J., Rivera V.M., Zhang J.Z. Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. Immunology 2002, 107:403-410.
46. Gori F., Mulinacci B., Massai L., Avolio C., Caragnano M., Peroni E., et al. IgG and IgM antibodies to the refolded MOG(1-125) extracellular domain in humans. J Neuroimmunol 2011, 233:216-220.
47. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999, 122(Pt 11):2089-2100.
48. Menge T., von Budingen H.C., Lalive P.H., Genain C.P. Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur J Immunol 2007, 37:3229-3239.
49. Lalive P.H., Menge T., Delarasse C., Della Gaspera B., Pham-Dinh D., Villoslada P., et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:2280-2285.
50. Zhou D., Srivastava R., Nessler S., Grummel V., Sommer N., Bruck W., et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103:19057-19062.
51. Brilot F., Dale R.C., Selter R.C., Grummel V., Kalluri S.R., Aslam M., et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009, 66:833-842.
52. Di Pauli F., Mader S., Rostasy K., Schanda K., Bajer-Kornek B., Ehling R., et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011, 138:247-254.
53. McLaughlin K.A., Chitnis T., Newcombe J., Franz B., Kennedy J., McArdel S., et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009, 183:4067-4076.
54. O'Connor K.C., McLaughlin K.A., De Jager P.L., Chitnis T., Bettelli E., Xu C., et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007, 13:211-217.
55. Lalive P.H., Hausler M.G., Maurey H., Mikaeloff Y., Tardieu M., Wiendl H., et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011, 17:297-302.
56. Sun J.B., Olsson T., Wang W.Z., Xiao B.G., Kostulas V., Fredrikson S., et al. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol 1991, 21:1461-1468.
57. Jaskiewicz E., Michalowska-Wender G., Pyszczek A., Wender M. Recombinant forms of myelin antigens expressed on Chinese hamster ovary (CHO) cells as a tool for identification of autoantibodies in serum of multiple sclerosis patients. Folia Neuropathol 2010, 48:45-48.
58. Dharmasaroja P. Specificity of autoantibodies to epitopes of myelin proteins in multiple sclerosis. J Neurol Sci 2003, 206:7-16.
59. Wajgt A., Gorny M. CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies. Acta Neurol Scand 1983, 68:337-343.
60. Moller J.R., Johnson D., Brady R.O., Tourtellotte W.W., Quarles R.H. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 1989, 22:55-61.
61. Baig S., Olsson T., Yu-Ping J., Hojeberg B., Cruz M., Link H. Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand J Immunol 1991, 33:73-79.
62. Podbielska M., Hogan E.L. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?. Mult Scler 2009, 15:1011-1029.
63. Ilyas A.A., Chen Z.W., Cook S.D. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2003, 139:76-80.
64. Kanter J.L., Narayana S., Ho P.P., Catz I., Warren K.G., Sobel R.A., et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006, 12:138-143.
65. Quintana F.J., Farez M.F., Viglietta V., Iglesias A.H., Merbl Y., Izquierdo G., et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A 2008, 105:18889-18894.
66. Brennan K.M., Galban-Horcajo F., Rinaldi S., O'Leary C.P., Goodyear C.S., Kalna G., et al. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol 2011, 238:87-95.
67. Szmyrka-Kaczmarek M., Pokryszko-Dragan A., Pawlik B., Gruszka E., Korman L., Podemski R., et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 2012, 21:412-420.
68. Villar L.M., Sadaba M.C., Roldan E., Masjuan J., Gonzalez-Porque P., Villarrubia N., et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194.
69. Thangarajh M., Gomez-Rial J., Hedstrom A.K., Hillert J., Alvarez-Cermeno J.C., Masterman T., et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler 2008, 14:1208-1213.
70. Villar L.M., Espino M., Cavanillas M.L., Roldan E., Urcelay E., de la Concha E.G., et al. Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clin Immunol 2010, 137:51-59.
71. Villar L.M., Masterman T., Casanova B., Gomez-Rial J., Espino M., Sadaba M.C., et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 2009, 211:101-104.
72. Fraussen J., Vrolix K., Claes N., Martinez-Martinez P., Losen M., Hupperts R., et al. Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients. J Neuroimmunol 2013, 261:98-107.
73. Kasai N., Pachner A.R., Yu R.K. Anti-glycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci 1986, 75:33-42.
74. Menge T., Lalive P.H., von Budingen H.C., Cree B., Hauser S.L., Genain C.P. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005, 116:453-459.
75. Lily O., Palace J., Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004, 127:269-279.
76. Eikelenboom M.J., Petzold A., Lazeron R.H., Silber E., Sharief M., Thompson E.J., et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003, 60:219-223.
77. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
78. Fialova L., Bartos A., Svarcova J., Zimova D., Kotoucova J., Malbohan I. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol 2013, 262:113-120.
79. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007, 116:100-107.
80. Ehling R., Lutterotti A., Wanschitz J., Khalil M., Gneiss C., Deisenhammer F., et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004, 10:601-606.
81. Huizinga R., Heijmans N., Schubert P., Gschmeissner S., t Hart B.A., Herrmann H., et al. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007, 66:295-304.
82. Bornstein N.M., Aronovich B., Korczyn A.D., Shavit S., Michaelson D.M., Chapman J. Antibodies to brain antigens following stroke. Neurology 2001, 56:529-530.
83. Couratier P., Yi F.H., Preud'homme J.L., Clavelou P., White A., Sindou P., et al. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci 1998, 154:137-145.
84. Semra Y.K., Seidi O.A., Sharief M.K. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002, 122:132-139.
85. Svarcova J., Fialova L., Bartos A., Steinbachova M., Malbohan I. Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. Eur J Neurol 2008, 15:1173-1179.
86. Fialova L., Bartos A., Soukupova J., Svarcova J., Ridzon P., Malbohan I. Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. Folia Biol (Praha) 2009, 55:23-26.
87. Smith P.R., Cooper J.M., Govan G.G., Riordan-Eva P., Harding A.E., Schapira A.H. Antibodies to human optic nerve in Leber's hereditary optic neuropathy. J Neurol Sci 1995, 130:134-138.
88. Skoda D., Kranda K., Bojar M., Glosova L., Baurle J., Kenney J., et al. Antibody formation against beta-tubulin class III in response to brain trauma. Brain Res Bull 2006, 68:213-216.
89. Terryberry J.W., Thor G., Peter J.B. Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol Aging 1998, 19:205-216.
90. Kotani M., Kawashima I., Ozawa H., Terashima T., Tai T. Differential distribution of major gangliosides in rat central nervous system detected by specific monoclonal antibodies. Glycobiology 1993, 3:137-146.
91. Acarin N., Rio J., Fernandez A.L., Tintore M., Duran I., Galan I., et al. Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 1996, 93:99-103.
92. Arnon R., Crisp E., Kelley R., Ellison G.W., Myers L.W., Tourtellotte W.W. Anti-ganglioside antibodies in multiple sclerosis. J Neurol Sci 1980, 46:179-186.
93. Bech E., Jakobsen J., Orntoft T.F. ELISA-type titertray assay of IgM anti-GM1 autoantibodies. Clin Chem 1994, 40:1331-1334.
94. Endo T., Scott D.D., Stewart S.S., Kundu S.K., Marcus D.M. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 1984, 132:1793-1797.
95. Mathiesen T., von Holst H., Fredrikson S., Wirsen G., Hederstedt B., Norrby E., et al. Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. J Neurol 1989, 236:238-242.
96. Stevens A., Weller M., Wietholter H. CSF and serum ganglioside antibody patterns in MS. Acta Neurol Scand 1992, 86:485-489.
97. Sadatipour B.T., Greer J.M., Pender M.P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998, 44:980-983.
98. Marconi S., Acler M., Lovato L., De Toni L., Tedeschi E., Anghileri E., et al. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. Mult Scler 2006, 12:302-308.
99. Mata S., Lolli F., Soderstrom M., Pinto F., Link H. Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. Mult Scler 1999, 5:379-388.
100. Ilyas A.A., Mithen F.A., Chen Z.W., Cook S.D. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barre syndrome. J Neurol Sci 1991, 102:67-75.
101. Nobile-Orazio E., Manfredini E., Carpo M., Meucci N., Monaco S., Ferrari S., et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994, 36:416-424.
102. van den Berg L.H., Lankamp C.L., de Jager A.E., Notermans N.C., Sodaar P., Marrink J., et al. Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993, 56:1164-1168.
103. Laffitte E., Burkhard P.R., Fontao L., Jaunin F., Saurat J.H., Chofflon M., et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis?. Br J Dermatol 2005, 152:537-540.
104. Derfuss T., Parikh K., Velhin S., Braun M., Mathey E., Krumbholz M., et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A 2009, 106:8302-8307.
105. Boronat A., Sepulveda M., Llufriu S., Sabater L., Blanco Y., Gabilondo I., et al. Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. J Neuroimmunol 2012, 244:103-106.
106. Josephson A., Trifunovski A., Widmer H.R., Widenfalk J., Olson L., Spenger C. Nogo-receptor gene activity: cellular localization and developmental regulation of mRNA in mice and humans. J Comp Neurol 2002, 453:292-304.
107. Wang X., Chun S.J., Treloar H., Vartanian T., Greer C.A., Strittmatter S.M. Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 2002, 22:5505-5515.
108. Onoue H., Satoh J.I., Ogawa M., Tabunoki H., Yamamura T. Detection of anti-Nogo receptor autoantibody in the serum of multiple sclerosis and controls. Acta Neurol Scand 2007, 115:153-160.
109. Kolln J., Ren H.M., Da R.R., Zhang Y., Spillner E., Olek M., et al. Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol 2006, 177:5652-5658.
110. Mathey E.K., Derfuss T., Storch M.K., Williams K.R., Hales K., Woolley D.R., et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007, 204:2363-2372.
111. DeVries G.H. Cryptic axonal antigens and axonal loss in multiple sclerosis. Neurochem Res 2004, 29:1999-2006.
112. Rawes J.A., Calabrese V.P., Khan O.A., DeVries G.H. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult Scler 1997, 3:363-369.
113. Baekkeskov S., Aanstoot H.J., Christgau S., Reetz A., Solimena M., Cascalho M., et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990, 347:151-156.
114. Hermitte L., Martin-Moutot N., Boucraut J., Barone R., Atlan-Gepner C., Seagar M., et al. Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome. J Clin Immunol 2000, 20:287-293.
115. Espay A.J., Chen R. Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 2006, 34:677-690.
116. Taplin C.E., Barker J.M. Autoantibodies in type 1 diabetes. Autoimmunity 2008, 41:11-18.
117. Walsh M.J., Murray J.M. Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J Clin Invest 1998, 101:1923-1931.
118. Sprinkle T.J. 2',3'-cyclic nucleotide 3'-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit Rev Neurobiol 1989, 4:235-301.
119. Bernier L., Alvarez F., Norgard E.M., Raible D.W., Mentaberry A., Schembri J.G., et al. Molecular cloning of a 2',3'-cyclic nucleotide 3'-phosphodiesterase: mRNAs with different 5' ends encode the same set of proteins in nervous and lymphoid tissues. J Neurosci 1987, 7:2703-2710.
120. Giulian D., Moore S. Identification of 2':3'-cyclic nucleotide 3'-phosphodiesterase in the vertebrate retina. J Biol Chem 1980, 255:5993-5995.
121. Lovato L., Cianti R., Gini B., Marconi S., Bianchi L., Armini A., et al. Transketolase and 2',3'-cyclic-nucleotide 3'-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. Mol Cell Proteomics 2008, 7:2337-2349.
122. Banki K., Colombo E., Sia F., Halladay D., Mattson D.H., Tatum A.H., et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 1994, 180:1649-1663.
123. Hotta S.S. Glucose metabolism in brain tissue: the hexosemonophosphate shunt and its role in glutathione reduction. J Neurochem 1962, 9:43-51.
124. Colombo E., Banki K., Tatum A.H., Daucher J., Ferrante P., Murray R.S., et al. Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. J Clin Invest 1997, 99:1238-1250.
125. Esposito M., Venkatesh V., Otvos L., Weng Z., Vajda S., Banki K., et al. Human transaldolase and cross-reactive viral epitopes identified by autoantibodies of multiple sclerosis patients. J Immunol 1999, 163:4027-4032.
126. Reindl M., Khantane S., Ehling R., Schanda K., Lutterotti A., Brinkhoff C., et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol 2003, 145:139-147.
127. Michel M., Fischer U., Meese E. A reticulon gene localized on chromosome 2 encodes a protein with increased autoimmunogenic properties in pilocytic astrocytoma patients. Electr J Pathol Histol 1999, 5:993-997.
128. Brosamle C., Huber A.B., Fiedler M., Skerra A., Schwab M.E. Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment. J Neurosci 2000, 20:8061-8068.
129. Buffo A., Zagrebelsky M., Huber A.B., Skerra A., Schwab M.E., Strata P., et al. Application of neutralizing antibodies against NI-35/250 myelin-associated neurite growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured purkinje cell axons. J Neurosci 2000, 20:2275-2286.
130. Wiessner C., Bareyre F.M., Allegrini P.R., Mir A.K., Frentzel S., Zurini M., et al. Anti-Nogo-A antibody infusion 24hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J Cereb Blood Flow Metab 2003, 23:154-165.
131. Archelos J.J., Trotter J., Previtali S., Weissbrich B., Toyka K.V., Hartung H.P. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol 1998, 43:15-24.
132. Niehaus A., Shi J., Grzenkowski M., Diers-Fenger M., Archelos J., Hartung H.P., et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann Neurol 2000, 48:362-371.
133. Trotter J. NG2-positive cells in CNS function and the pathological role of antibodies against NG2 in demyelinating diseases. J Neurol Sci 2005, 233:37-42.
134. Morita K., Sasaki H., Fujimoto K., Furuse M., Tsukita S. Claudin-11/OSP-based tight junctions of myelin sheaths in brain and Sertoli cells in testis. J Cell Biol 1999, 145:579-588.
135. Chow E., Mottahedeh J., Prins M., Ridder W., Nusinowitz S., Bronstein J.M. Disrupted compaction of CNS myelin in an OSP/Claudin-11 and PLP/DM20 double knockout mouse. Mol Cell Neurosci 2005, 29:405-413.
136. Bronstein J.M., Lallone R.L., Seitz R.S., Ellison G.W., Myers L.W. A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic. Neurology 1999, 53:154-161.
137. Vu T., Myers L.W., Ellison G.W., Mendoza F., Bronstein J.M. T-cell responses to oligodendrocyte-specific protein in multiple sclerosis. J Neurosci Res 2001, 66:506-509.
138. Kaushansky N., Hemo R., Eisenstein M., Ben-Nun A. OSP/claudin-11-induced EAE in mice is mediated by pathogenic T cells primarily governed by OSP192Y residue of major encephalitogenic region OSP179-207. Eur J Immunol 2007, 37:2018-2031.
139. van Noort J.M., Bsibsi M., Gerritsen W.H., van der Valk P., Bajramovic J.J., Steinman L., et al. Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol 2010, 69:694-703.
140. Agius M.A., Kirvan C.A., Schafer A.L., Gudipati E., Zhu S. High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease. Acta Neurol Scand 1999, 100:139-147.
141. van Noort J.M., Verbeek R., Meilof J.F., Polman C.H., Amor S. Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire. Mult Scler 2006, 12:287-293.
142. Celet B., Akman-Demir G., Serdaroglu P., Yentur S.P., Tasci B., van Noort J.M., et al. Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. J Neurol 2000, 247:935-939.
143. Hegen H., Wanschitz J., Ehling R., Deisenhammer F., Loscher W.N., Reindl M., et al. Anti-alpha B-crystallin immunoreactivity in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2010, 15:150-152.
144. Petzold A., Plant G.T. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev 2014, 13:539-545.
145. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
146. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
147. Vincent A. Developments in autoimmune channelopathies. Autoimmun Rev 2013, 12:678-681.
148. Waters P., Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008, 15:99-105.
149. Srivastava R., Aslam M., Kalluri S.R., Schirmer L., Buck D., Tackenberg B., et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123.
150. Somers V., Govarts C., Somers K., Hupperts R., Medaer R., Stinissen P. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J Immunol 2008, 180:3957-3963.
151. Zhang Z., Zariwala M.A., Mahadevan M.M., Caballero-Campo P., Shen X., Escudier E., et al. A heterozygous mutation disrupting the SPAG16 gene results in biochemical instability of central apparatus components of the human sperm axoneme. Biol Reprod 2007, 77:864-871.
152. Pennarun G., Bridoux A.M., Escudier E., Dastot-Le Moal F., Cacheux V., Amselem S., et al. Isolation and expression of the human hPF20 gene orthologous to Chlamydomonas PF20: evaluation as a candidate for axonemal defects of respiratory cilia and sperm flagella. Am J Respir Cell Mol Biol 2002, 26:362-370.
153. Rouwette M., Somers K., Govarts C., De Deyn P.P., Hupperts R., Van Wijmeersch B., et al. Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. J Neurochem 2012, 123:568-577.
154. Rouwette M., Noben J.P., Van Horssen J., Van Wijmeersch B., Hupperts R., Jongen P.J., et al. Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis. J Neurochem 2013, 126:483-492.
155. Erdag E., Tuzun E., Ugurel E., Cavus F., Sehitoglu E., Giris M., et al. Switch-associated protein 70 antibodies in multiple sclerosis: relationship between increased serum levels and clinical relapse. Inflamm Res 2012, 61:927-930.
156. Turkoglu R., Gencer M., Ekmekci D., Ulusoy C., Erdag E., Sehitoglu E., et al. Switch-associated protein 70 antibodies in multiple sclerosis: possible association with disease progression. Med Princ Pract 2014, 23:239-245.
157. Brosnan C.F., Battistini L., Gao Y.L., Raine C.S., Aquino D.A. Heat shock proteins and multiple sclerosis: a review. J Neuropathol Exp Neurol 1996, 55:389-402.
158. Cid C., Alvarez-Cermeno J.C., Camafeita E., Salinas M., Alcazar A. Antibodies reactive to heat shock protein 90 induce oligodendrocyte precursor cell death in culture. Implications for demyelination in multiple sclerosis. FASEB J 2004, 18:409-411.
159. Cid C., Regidor I., Alcazar A. Anti-heat shock protein 90beta antibodies are detected in patients with multiple sclerosis during remission. J Neuroimmunol 2007, 184:223-226.
160. Chiba S., Yokota S., Yonekura K., Tanaka S., Furuyama H., Kubota H., et al. Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J Neurol Sci 2006, 241:39-43.
161. Yokota S., Chiba S., Furuyama H., Fujii N. Cerebrospinal fluids containing anti-HSP70 autoantibodies from multiple sclerosis patients augment HSP70-induced proinflammatory cytokine production in monocytic cells. J Neuroimmunol 2010, 218:129-133.
162. Williamson R.A., Burgoon M.P., Owens G.P., Ghausi O., Leclerc E., Firme L., et al. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci U S A 2001, 98:1793-1798.
163. Op De Beeck K., Vermeersch P., Verschueren P., Westhovens R., Marien G., Blockmans D., et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012, 12:137-143.
164. Sueoka E., Yukitake M., Iwanaga K., Sueoka N., Aihara T., Kuroda Y. Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. Ann Neurol 2004, 56:778-786.
165. Mayo I., Arribas J., Villoslada P., Alvarez DoForno R., Rodriguez-Vilarino S., Montalban X., et al. The proteasome is a major autoantigen in multiple sclerosis. Brain 2002, 125:2658-2667.
166. Beyer N.H., Milthers J., Bonde Lauridsen A.M., Houen G., Lautrup Frederiksen J. Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis. Scand J Clin Lab Invest 2007, 67:696-706.
167. Thuy-Tien H., Haugen M., Aarseth J., Storstein A., Vedeler C.A. Proteasome antibodies in patients with cancer or multiple sclerosis. Scand J Immunol 2008, 67:400-403.
168. Chiba A., Kusunoki S., Shimizu T., Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992, 31:677-679.
169. Rieder F., Schleder S., Wolf A., Dirmeier A., Strauch U., Obermeier F., et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010, 16:1367-1375.
170. Schwarz M., Spector L., Gortler M., Weisshaus O., Glass-Marmor L., Karni A., et al. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 2006, 244:59-68.
171. Brettschneider J., Jaskowski T.D., Tumani H., Abdul S., Husebye D., Seraj H., et al. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 2009, 217:95-101.
172. Freedman M.S., Laks J., Dotan N., Altstock R.T., Dukler A., Sindic C.J. Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult Scler 2009, 15:422-430.
173. Freedman M.S., Metzig C., Kappos L., Polman C.H., Edan G., Hartung H.P., et al. Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler 2012, 18:966-973.
174. Arrambide G., Espejo C., Yarden J., Fire E., Spector L., Dotan N., et al. Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis. PLoS One 2013, 8:e59953.
175. Forghani B., Cremer N.E., Johnson K.P., Fein G., Likosky W.H. Comprehensive viral immunology of multiple sclerosis. III. Analysis of CSF antibodies by radioimmunoassay. Arch Neurol 1980, 37:616-619.
176. Gilden D.H. Infectious causes of multiple sclerosis. Lancet Neurol 2005, 4:195-202.
177. Sargsyan S.A., Shearer A.J., Ritchie A.M., Burgoon M.P., Anderson S., Hemmer B., et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010, 74:1127-1135.
178. Vaughan J.H., Riise T., Rhodes G.H., Nguyen M.D., Barrett-Connor E., Nyland H. An Epstein-Barr virus-related cross reactive autoimmune response in multiple sclerosis in Norway. J Neuroimmunol 1996, 69:95-102.
179. Teunissen C., Menge T., Altintas A., Alvarez-Cermeno J.C., Bertolotto A., Berven F.S., et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013, 19:1802-1809.